Literature DB >> 7679649

Human T cell autoimmunity against myelin basic protein: CD4+ cells recognizing epitopes of the T cell receptor beta chain from a myelin basic protein-specific T cell clone.

G Saruhan-Direskeneli1, F Weber, E Meinl, M Pette, G Giegerich, A Hinkkanen, J T Epplen, R Hohlfeld, H Wekerle.   

Abstract

We have investigated whether the normal immune system contains T cells that are able to recognize T cell receptor (TcR) determinants of autologous autoantigen-specific T cells. The T cell clone HW.BP3, specific for myelin basic protein (MBP) was isolated from a healthy donor. HW.BP3 is restricted by HLA-DR2a, and reacts to human MBP 139-153. The expressed alpha beta TcR genes of HW.BP3 were cloned and sequenced, and the sequences analyzed for potential T cell epitopes. Two synthetic peptides, one from the VDJ beta junctional (beta 1) and one from the V beta region (beta 2) of the TcR of HW.BP3, were used to select four TcR peptide-specific T cell lines from the donor of HW.BP3. All anti-TcR lines had the phenotype CD3+/CD4+/HLA-DR+/CD25+/CD45RO+, and recognized the antigen in the context of HLA-DR. Three anti-TcR lines, which had been selected for reactivity to peptide beta 1, recognized exclusively this peptide restricted by HLA-DR2b. One anti-TcR line, selected for peptide beta 2, responded to both peptides beta 1 and beta 2 when presented by autologous blood mononuclear cells, but not by HLA-DR2a- or HLA-DR2b-transfected L cells. All TcR peptide-specific T cell lines were efficiently cytotoxic. They specifically lysed autologous macrophages or HW.BP3 line cells in the presence of exogenous peptide antigen. In contrast, HW.BP3 did not present endogenous TcR peptides to the anti-TcR lines. The results demonstrate that the normal human immune system contains not only autoantigen-specific T cells, but also T cells that recognize antigenic determinants of autologous autoreactive TcR.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679649     DOI: 10.1002/eji.1830230235

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

Review 1.  Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.

Authors:  Reinhard Hohlfeld; Hartmut Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

Review 2.  Homeostatic control of immunity by TCR peptide-specific Tregs.

Authors:  Vipin Kumar
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

Review 3.  TCR peptide therapy in human autoimmune diseases.

Authors:  A A Vandenbark; E Morgan; R Bartholomew; D Bourdette; R Whitham; D Carlo; D Gold; G Hashim; H Offner
Journal:  Neurochem Res       Date:  2001-06       Impact factor: 3.996

4.  Anti-T-cell humoral and cellular responses in healthy BALB/c mice following immunization with ovalbumin or ovalbumin-specific T cells.

Authors:  Xiao-Yu Zhang; Xiang-Guo Liu; Wei Wang; Wen-Chao Wang; Xiao-Ming Gao
Journal:  Immunology       Date:  2003-04       Impact factor: 7.397

5.  Transformation of human T-cell clones by Herpesvirus saimiri: intact antigen recognition by autonomously growing myelin basic protein-specific T cells.

Authors:  F Weber; E Meinl; K Drexler; A Czlonkowska; S Huber; H Fickenscher; I Müller-Fleckenstein; B Fleckenstein; H Wekerle; R Hohlfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

6.  The human myelin basic protein gene is included within a 179-kilobase transcription unit: expression in the immune and central nervous systems.

Authors:  T M Pribyl; C W Campagnoni; K Kampf; T Kashima; V W Handley; J McMahon; A T Campagnoni
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

7.  CDR1 T-cell receptor beta-chain peptide induces major histocompatibility complex class II-restricted T-T cell interactions.

Authors:  C P Broeren; M A Lucassen; M J van Stipdonk; R van der Zee; C J Boog; J G Kusters; W van Eden
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

Review 8.  [Update on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis].

Authors:  C Kleinschnitz; S G Meuth; B C Kieseier; H Wiendl
Journal:  Nervenarzt       Date:  2007-08       Impact factor: 1.214

9.  IL-10 is necessary and sufficient for autoimmune diabetes in conjunction with NOD MHC homozygosity.

Authors:  M S Lee; R Mueller; L S Wicker; L B Peterson; N Sarvetnick
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.